SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 4, 2004
------------
Progenics Pharmaceuticals, Inc.
-----------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-23143 13-3379479
---------------------------- ----------- -------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York 10591
--------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 789-2800
----------------
---------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 7. Financial Statements and Exhibits
(c) Exhibits
Exhibit 99.1 Description
Press Release dated May 4, 2004 (filed herewith).
Item 9. Regulation FD Disclosure.
On May 4, 2004, Progenics Pharmaceuticals, Inc. issued a press release
announcing the initiation of a phase 1 clinical trial of its investigational
drug PRO 140, a humanized monoclonal antibody viral-entry inhibitor, designed to
prevent HIV (human immunodeficiency virus, the causative agent of AIDS) from
gaining access to healthy cells of the human immune system by blocking the CCR5
coreceptor, one of the principal portals HIV uses to enter cells. A copy of the
press release is attached as Exhibit 99.1.
The information furnished pursuant to Item 9 in this Form 8-K shall not
be deemed to be "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section,
unless we specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no
duty or obligation to publicly update or revise the information furnished
pursuant to Item 9 in this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ PHILIP K. YACHMETZ
-----------------------------------------
Philip K. Yachmetz
Vice President, General Counsel and Secretary
Date: May 4, 2004